Literature DB >> 1902178

The presence of eosinophil-activating mediators in sera from individuals with Schistosoma mansoni infections.

G Mazza1, K J Thorne, B A Richardson, A E Butterworth.   

Abstract

IgG antibodies and eosinophils kill schistosomula of Schistosoma mansoni in vitro, and there is now evidence to suggest that the main factor that contributes to the expression of purified IgG effector function is the degree of activation of the donor's eosinophils. This study was designed to identify serum-derived activating factors in sera from individuals infected with S. mansoni. Such activating factors may be responsible for enhancing eosinophil cytotoxicity against schistosomula. Serum-borne mediators were prepared by fractionation of sera from infected individuals by gel filtration high-performance liquid chromatography. The eosinophil-stimulating activity of these mediators was assayed by a new method which depends on the increased expression of the CR3 alpha chain (CD11b) on the surface of activated eosinophils. Sera from infected individuals exhibited different levels of eosinophil activation, and activation appeared to be due to several serum factors, including interleukin 5. In conclusion, our results suggest that eosinophil-activating factors present in infection sera may not only be responsible for enhancing eosinophil cytotoxicity but also be necessary for its expression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1902178     DOI: 10.1002/eji.1830210407

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  2 in total

Review 1.  The eosinophil leukocyte: controversies of recruitment and function.

Authors:  L P Bignold
Journal:  Experientia       Date:  1995-04-15

2.  Influence of histamine receptor antagonists on the dynamics of the cutaneous hypersensitivity reaction in patients infected with schistosoma haematobium.

Authors:  J R Snyman; D K Sommers; M D Gregorowski
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.